Literature DB >> 11517408

A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy.

W J Atwood1.   

Abstract

The human polyomavirus, JCV, is the etiologic agent of a fatal central nervous system (CNS) demyelinating disease known as progressive multifocal leukoencephalopathy (PML). PML occurs predominantly in immunosuppressed patients and remains an intractable complication in AIDS. To date, there are no effective therapies to treat PML. We previously demonstrated that the neuroleptic drug, chlorpromazine, inhibits the endocytic pathway used by JCV to infect glial cells. In this paper, we demonstrate that nontoxic doses of chlorpromazine are effective at inhibiting JCV multiplication and spread in a tissue culture model. The clinical efficacy of this drug or related compounds in treating PML has not been evaluated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517408     DOI: 10.1080/13550280152537157

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  12 in total

1.  Evaluation of the role of cytokine activation in the multiplication of JC virus (JCV) in human fetal glial cells.

Authors:  W J Atwood; L Wang; L C Durham; K Amemiya; R G Traub; E O Major
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

2.  Inhibition of HIV infection of H9 cells by chlorpromazine derivatives.

Authors:  I Hewlett; S Lee; J Molnar; S Foldeak; P S Pine; J L Weaver; A Aszalos
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-05-01

3.  Internalization and recycling of transferrin and its receptor. Effect of trifluoperazine on recycling in human erythroleukemic cells.

Authors:  R C Hunt; L Marshall-Carlson
Journal:  J Biol Chem       Date:  1986-03-15       Impact factor: 5.157

4.  Inhibition of SV40 DNA replication in vitro by chlorpromazine.

Authors:  H Hirai; S Takeda; S Natori; K Sekimizu
Journal:  Biol Pharm Bull       Date:  1993-06       Impact factor: 2.233

5.  Establishment of a line of human fetal glial cells that supports JC virus multiplication.

Authors:  E O Major; A E Miller; P Mourrain; R G Traub; E de Widt; J Sever
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

6.  JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis.

Authors:  M T Pho; A Ashok; W J Atwood
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Examination of potential inhibitors of hepatitis A virus uncoating.

Authors:  N E Bishop
Journal:  Intervirology       Date:  1998       Impact factor: 1.763

8.  Extension of JC virus host range to monkey cells by insertion of a simian virus 40 enhancer into the JC virus regulatory region.

Authors:  D A Vacante; R Traub; E O Major
Journal:  Virology       Date:  1989-06       Impact factor: 3.616

9.  Inhibition of arenavirus multiplication in vitro by phenotiazines.

Authors:  N A Candurra; L Maskin; E B Damonte
Journal:  Antiviral Res       Date:  1996-07       Impact factor: 5.970

10.  Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids.

Authors:  C K Liu; G Wei; W J Atwood
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

View more
  16 in total

Review 1.  Challenges for clinical trials to treat progressive multifocal leukoencephalopathy.

Authors:  David B Clifford
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 2.  Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.

Authors:  Eric M L Williamson; Joseph R Berger
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy.

Authors:  S Baum; A Ashok; G Gee; S Dimitrova; W Querbes; J Jordan; Walter J Atwood
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

4.  Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy.

Authors:  Pankaj Seth; Frank Diaz; Eugene O Major
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

Review 5.  Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Eugene O Major
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

Review 6.  Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

7.  Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies.

Authors:  Parmjeet Randhawa; Raphael Viscidi; Joseph J Carter; Denise A Galloway; Tim D Culp; Cathy Huang; Bala Ramaswami; Neil D Christensen
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

8.  Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres.

Authors:  Joshua J Reineke; Daniel Y Cho; Yu-Ting Dingle; A Peter Morello; Jules Jacob; Christopher G Thanos; Edith Mathiowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-06       Impact factor: 11.205

Review 9.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

10.  Scavenger receptor mediated endocytosis of silver nanoparticles into J774A.1 macrophages is heterogeneous.

Authors:  Hongyun Wang; Linxi Wu; Björn M Reinhard
Journal:  ACS Nano       Date:  2012-07-24       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.